Evidence map›Paper›PMID 40301136›Full record

ArticleVirchows Archiv : an international journal of pathology2025

Evaluating CSPG4 expression in esophageal basaloid squamous cell carcinoma and conventional squamous cell carcinoma: a multi-institutional retrospective study in China.

Dongxian Jiang, Chen Xu, Yan Li, Ling Nie, Xueqin Tao, Xiaomu Hu, Ming Yang, Xuefei Li, Xiaona Chang, Xinran Wang and 25 more

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Dongxian Jiang *Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China.
Chen Xu *Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China.
Yan Li *Department of Pathology, Cancer Hospital, National Cancer Center, National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P. R. China.
Ling Nie *Department of Pathology, The Affiliated Drum Tower Hospital, Nanjing University Medical School, Jiangsu Province, Nanjing, 210008, P. R. China.
Xueqin TaoDepartment of Pathology, The First Affiliated Hospital of Nanchang University, Jiangxi Province, Nanchang, 330006, P. R. China.
Xiaomu HuDepartment of Pathology, Huashan Hospital, Fudan University, Shanghai, 200040, P. R. China.
Ming YangDepartment of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Province, Wuhan, 430022, China.
Xuefei LiDepartment of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Province, Wuhan, 430022, China.
Xiaona ChangDepartment of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Province, Wuhan, 430022, China.
Xinran WangDepartment of Pathology, Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Hebei Province, Shijiazhuang, 050000, P. R. China.
Xiaoqun YangDepartment of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, P. R. China.
Qiang ZhengDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, P. R. China.
Haohua TengDepartment of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, P. R. China.
Yayun HeDepartment of Pathology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, P. R. China.
Wei YuanDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China.
Yuhao XiaoDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China.
Minying DengDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China.
Yufeng LiuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China.
Zixiang YuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China.
Qi SongDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China.
Jiamei YaoDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China.
Xiaolei ZhangDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China.
Lei XuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China.
Jieakesu SuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China.
Miaoxia HeDepartment of Pathology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, P. R. China.
Yuchen HanDepartment of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, P. R. China.
Yuan LiDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, P. R. China.
Chaofu WangDepartment of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, P. R. China.
Yueping LiuDepartment of Pathology, Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Hebei Province, Shijiazhuang, 050000, P. R. China.
Xiu NieDepartment of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Province, Wuhan, 430022, China.
Xiangshan FanDepartment of Pathology, The Affiliated Drum Tower Hospital, Nanjing University Medical School, Jiangsu Province, Nanjing, 210008, P. R. China.
Liyan XueDepartment of Pathology, Cancer Hospital, National Cancer Center, National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P. R. China.
Jinhong MeiDepartment of Pathology, The First Affiliated Hospital of Nanchang University, Jiangxi Province, Nanchang, 330006, P. R. China. mjhdoctor@126.com.
Feng TangDepartment of Pathology, Huashan Hospital, Fudan University, Shanghai, 200040, P. R. China. tangfeng1966@sohu.com.
Yingyong HouDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China. houyingyong@aliyun.com.ORCID http://orcid.org/0000-0001-9156-2305

Funding

National Clinical Key Specialty-Pathology Department YWP2023-001National Natural Science Foundation of China 81702372Shanghai Municipal Health Commission 20214Y0275Shanghai Natural Science Foundation of China 23ZR1410000Shanghai Natural Science Foundation of China 23ZR1410200
6 · The paper itself

Abstract

Esophageal basaloid squamous cell carcinoma (EBSCC) is a rare subtype of esophageal squamous cell carcinoma (ESCC) that might be misdiagnosed or missed in clinical practice. Through RNA sequencing on 20 pure EBSCC and 11 poorly differentiated ESCC samples, we identified CSPG4 as a potential marker for EBSCC at the mRNA level, and verified with CSPG4 immunohistochemical staining in these cases. Then we assessed the value of CSPG4 expression in differential diagnosis and prognosis in EBSCC cases (n = 360) and conventional ESCC cases (n = 160) from 11 different institutions with whole-tissue sections. CSPG4 had acceptable discriminatory capacity for EBSCC, with an AUC ROC of 0.891. The optimal cutoff value for the H-score determined by ROC curve analysis was 77.5, with 82.7% sensitivity and 79.9% specificity. In well-moderately differentiated ESCC with CSPG4 expression, staining was mostly observed on the edge of the tumor nest or infiltration front, with different expression pattern from EBSCC. The H-scores of CSPG4 expression for the EBSCC component were higher than those for other components in the same tissue section (P < 0.05). The expression level of CSPG4 was similar in groups with different percentages of the EBSCC component (P > 0.05). In additional 505 ESCC patients, patients with high CSPG4 expression had decreased DFS and OS, especially in stage I-II disease (P < 0.001). The similar prognostic significance was also found in EBSCC. Our data indicate that CSPG4 is not only a sensitive but also a specific marker for the diagnosis of EBSCC. CSPG4 might also be a prognostic marker for ESCC.

Indexed as

Chondroitin sulfate proteoglycan 4 (CSPG4)Diagnostic and prognostic markerEsophageal basaloid squamous cell carcinoma (EBSCC)Esophageal squamous cell carcinoma (ESCC)

Identifiers

PMID40301136

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.